ATE483972T1 - Reagenzien und verfahren für krebsprognose und pathologische einstufung - Google Patents

Reagenzien und verfahren für krebsprognose und pathologische einstufung

Info

Publication number
ATE483972T1
ATE483972T1 AT07757161T AT07757161T ATE483972T1 AT E483972 T1 ATE483972 T1 AT E483972T1 AT 07757161 T AT07757161 T AT 07757161T AT 07757161 T AT07757161 T AT 07757161T AT E483972 T1 ATE483972 T1 AT E483972T1
Authority
AT
Austria
Prior art keywords
reagents
methods
cancer prognosis
pathological grading
grading
Prior art date
Application number
AT07757161T
Other languages
English (en)
Inventor
Gary Pestano
Linda Samadzadeh
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of ATE483972T1 publication Critical patent/ATE483972T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07757161T 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung ATE483972T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77456306P 2006-02-16 2006-02-16
PCT/US2007/062362 WO2007095644A2 (en) 2006-02-16 2007-02-16 Reagents and methods for cancer prognosis and pathological staging

Publications (1)

Publication Number Publication Date
ATE483972T1 true ATE483972T1 (de) 2010-10-15

Family

ID=38335516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07757161T ATE483972T1 (de) 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung

Country Status (10)

Country Link
US (2) US20070207489A1 (de)
EP (2) EP2290361A1 (de)
JP (1) JP5143026B2 (de)
CN (2) CN101384901A (de)
AT (1) ATE483972T1 (de)
AU (1) AU2007214427B2 (de)
CA (1) CA2642542C (de)
DE (1) DE602007009645D1 (de)
ES (1) ES2354181T3 (de)
WO (1) WO2007095644A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
WO2010017822A1 (en) 2008-08-15 2010-02-18 Visiopharm A/S A method and a system for determining a target in a biological sample by image analysis
US9697582B2 (en) 2006-11-16 2017-07-04 Visiopharm A/S Methods for obtaining and analyzing images
WO2008143849A2 (en) 2007-05-14 2008-11-27 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
JP5593221B2 (ja) 2007-06-15 2014-09-17 ヒストロックス,インコーポレイテッド. 顕微鏡機器を標準化するための方法およびシステム
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
EP3216874A1 (de) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Verfahren zum stratifizieren und annotieren der behandlungsoptionen eines krebsmedikaments
CN102165489B (zh) 2008-09-16 2015-11-25 赫斯托克斯公司 生物标志物表达的可再现量化
EP2350320A4 (de) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings Verfahren und systeme zur verwendung von exosomen zur bestimmung von phänotypen
WO2010066252A1 (en) * 2008-12-09 2010-06-17 Dako Denmark A/S Method for evaluating pre-treatment
US20110306514A1 (en) 2009-01-14 2011-12-15 United States Department of Health and Human Services Ratio based biomarkers and methods of use thereof
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
RU2012148816A (ru) * 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
CN101876659B (zh) * 2010-06-29 2013-02-13 同济大学 用于检测肿瘤的量子点试剂盒
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
US9410207B2 (en) * 2011-12-30 2016-08-09 Abbott Molecular Inc. Method and compositions for detecting epidermal growth factor receptor variant forms in cancer cells
WO2015028974A2 (en) * 2013-08-30 2015-03-05 Nestec S.A. Polyp recurrence
EP3100054B1 (de) * 2014-01-28 2022-02-23 Quest Diagnostics Investments Incorporated Verfahren und zusammensetzungen zum nachweis eines adenoma-adenokarzinom-übergangs bei krebs
CN103882139B (zh) * 2014-04-04 2015-06-03 上海赛安生物医药科技有限公司 一种用于化疗方案选择的多重基因检测试剂盒
US10746740B2 (en) 2015-01-22 2020-08-18 Konica Minolta, Inc. Biological substance quantitation method, pathological diagnosis support system, and recording medium storing computer readable program
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
CN107688092B (zh) * 2017-08-18 2020-05-19 国家纳米科学中心 一种用于癌症患者预后评估的方法
KR102655467B1 (ko) 2018-02-28 2024-04-08 니토 보세키 가부시기가이샤 고정화 세포 또는 ffpe 조직 절편으로부터 항원성을 증강한 세포핵을 탈리하는 방법 그리고 그것을 위한 항원 부활제 및 키트

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US6872817B1 (en) 1986-01-16 2005-03-29 The Regents Of The Univ. Of California Method of staining target interphase chromosomal DNA
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
WO2001092338A1 (en) * 2000-06-01 2001-12-06 The Brigham And Women's Hospital, Inc. Diagnosis of endometrial precancers
BR0207290A (pt) * 2001-02-16 2005-06-07 Immunivest Corp Método para analisar um paciente quanto à presença de uma malignidade, célula maligna isolada das células cultivadas, vacina de tumor, molécula associada com diátese de tumor alterada, métodos para determinar alterações em moléculas associadas com diátese de tumor como um meio para predizer a eficácia da terapia, como um meio para analisar dosagem apropriada para terapia, como um meio para monitorar eficácia da terapia, como um meio para analisar progressão de câncer, para realizar uma biópsia de corpo inteiro em um paciente, e para identificar alterações em uma célula de tumor circulante relativamente a células presentes numa massa de tumor in situ, e, kit de teste para analisar uma amostra de paciente quanto à presença de uma célula maligna não-hematopoiética
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
EP1521747B1 (de) * 2002-07-15 2018-09-05 Symphony Evolution, Inc. Modulatoren von rezeptor-typ-kinase und anwendungsverfahren
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
JP2007506442A (ja) * 2003-05-30 2007-03-22 ゲノミック ヘルス, インコーポレイテッド Egfr阻害薬への応答に関する遺伝子発現マーカー
DE10345021A1 (de) * 2003-09-23 2005-05-04 Univ Potsdam Verfahren zur nichtinvasiven Früherkennung von Dickdarmkrebs und/oder Darmkrebsvorläuferzellen
CA2569079A1 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
AU2005250484B2 (en) * 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
CA2583389A1 (en) * 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
EP2473495A1 (de) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmazeutische verbindungen

Also Published As

Publication number Publication date
US20070207489A1 (en) 2007-09-06
CN101384901A (zh) 2009-03-11
EP1984735A2 (de) 2008-10-29
JP5143026B2 (ja) 2013-02-13
US20100184099A1 (en) 2010-07-22
CA2642542A1 (en) 2007-08-23
EP2290361A1 (de) 2011-03-02
DE602007009645D1 (de) 2010-11-18
WO2007095644A2 (en) 2007-08-23
EP1984735B1 (de) 2010-10-06
AU2007214427A1 (en) 2007-08-23
CN104749378A (zh) 2015-07-01
AU2007214427B2 (en) 2011-11-10
ES2354181T3 (es) 2011-03-10
CA2642542C (en) 2012-09-25
JP2009527740A (ja) 2009-07-30
WO2007095644A3 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
DE602007009645D1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
EP2047262A4 (de) Verfahren zur krebsprognose auf der basis subzellulärer lokalisierung von biomarkern
EP1897940A4 (de) Zusammensetzung und verfahren zur diagnose von speiseröhrenkrebs sowie der metastasierung von speiseröhrenkrebs
EP1969363A4 (de) Verfahren und markerkombinationen zum screening auf eine veranlagung zu lungenkrebs
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
WO2008154098A3 (en) Reagents and methods for mirna expression analysis and identification of cancer biomarkers
EP1991701A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von krebs
DE112006001755A5 (de) EU/TB-Chelat-basiertes fluoreszenzspektroskopisches Verfahren zum Nachweis von Analyten
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
ATE410524T1 (de) Verfahren und nukleinsäuren für die analyse von zellulären proliferationsstörungen
TWI317811B (de)
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
EP1599603A4 (de) Diagnose- und prognoseverfahren von pankreaskrebs
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
ATE557276T1 (de) Spezifisches verfahren zum krebsnachweis
ATE408839T1 (de) Tumor marker für urothelialen krebs
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis
WO2007082073A8 (en) Biomarkers for oral tongue cancer metastasis and extracapsular spread (ecs)
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
ATE433158T1 (de) System und verfahren zur erkennung der breite eines datenbusses
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
WO2008104985A3 (en) Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers
DE60317606D1 (de) Marker für Brustkrebsprognose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties